In two open-label trials of higher-risk, largely vaccinated outpatients with COVID-19 (4,232 randomised), nirmatrelvir-ritonavir vs usual care did not reduce 28-day hospitalisation or death (0.8% vs 0.7% and 0.6% vs 1.2%).
RCTn = 4,232
Butler et al. Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients